Study on French medical insurance payment policy for innovative medical products paid under DRG
- VernacularTitle:DRG付费下法国创新医药产品医保支付政策研究
- Author:
Jiaming LI
1
;
Jinxi DING
1
,
2
;
Shengxin HUANG
1
;
Yuqing REN
1
;
Zhaoming LIN
1
Author Information
1. School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing 211198，China
2. Research Center of Medical Market Access Policy，China Pharmaceutical University，Nanjing 211198，China
- Publication Type:Journal Article
- Keywords:
diagnosis-related group;
additional list system;
innovative pharmaceutical products;
medical insurance payment
- From:
China Pharmacy
2023;34(12):1409-1414
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the implementation experience of France’s additional list system for innovative medical products， and to provide reference for China to support medical institutions to use innovative medical products. METHODS Taking France as a case study， using policy analysis method， this paper systematically studied the practice of establishing additional list system to compensate for innovative medical products in France under diagnosis-related group （DRG） payment， including the establishment background， selection procedure and implementation effect. The suggestions were provided on the medical insurance payment methods for innovative medical products in China. RESULTS & CONCLUSIONS The additional list system established a compensation and payment system for innovative medical products with significant clinical efficacy but high treatment cost， covering four stages： application， evaluation， payment and adjustment， which effectively reduced the drug burden on medical institutions， promoted the use of innovative pharmaceutical products by medical institutions， and stimulated the innovation drive of the pharmaceutical industry， but at the same time brought payment pressure to the medical insurance fund. With the rapid spread of our DRG/diagnosis-intervention packet payment reform of China， some regions have also explored the establishment of a compensation and payment mechanism for innovative medical products， but there are still imperfections. We can refer to the implementation experience of the French additional list system and establish an effective compensation and payment system for innovative medical products starting from the establishment of selection criteria， the selection of compensation mode and the implementation of dynamic adjustment.
